"R&D Expenses Rise as Preparations for CARTISTEM's U.S. Clinical Trial and Marketing Authorization Progress"

MEDIPOST disclosed on November 16 that it recorded cumulative consolidated revenue of 57.5 billion won and an operating loss of 61 billion won for the first three quarters of this year. Revenue increased 3.1% year over year. On a standalone basis, revenue was 61.5 billion won and the operating loss was 800 million won.


Medipost company logo image. Medipost

Medipost company logo image. Medipost

View original image

The company said research and development expenses increased as it progressed with clinical trials and preparations for marketing authorization of CARTISTEM, a stem cell treatment for knee osteoarthritis, in the United States and Japan.


In Japan, the company is organizing data from the Phase 3 clinical trial and preparing its submission to regulators for a marketing authorization application. In the United States, patients are being dosed in the Phase 3 clinical trial. The company said the related R&D spending is a proactive investment in global commercialization.


A MEDIPOST representative said, "The third-quarter consolidated results reflect costs for key clinical trials and regulatory preparations for the commercialization of CARTISTEM in the United States and Japan. We will proceed without disruption with dosing in the U.S. Phase 3 trial and preparations for the marketing authorization application in Japan to enhance corporate value."



In the third quarter, MEDIPOST appointed Min Ho-seong as its new CEO and reorganized its management structure. Min oversees global operations, including the company's U.S. and Japanese subsidiaries, overseas clinical trials, and business development (BD) in key regions. The company plans to release interim results from CARTISTEM's real-world evidence (RWE) study and announce future development plans for SMUP-IA-01 within this year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing